Thus, improving first-line treatment outcomes remains an unmet need also for patients with advanced EGFR mutant NSCLC; in fact, it is dismal the evidence that, although an effective treatment such as osimertinib, about 25% of patients do not manage to be treated with a second-line treatment because of death due to lung cancer [57,58]. The gene discussed is EGFR; the disease is lung carcinoma.